Trial site
Memorial Sloan Kettering Cancer Center - Basking Ridge
Basking Ridge, New Jersey 07920, United StatesNot linked to an institution yet
- 13running trials
- 4closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 29 trials
- Phase 35 trials
- Phase 1/22 trials
- Status
- Active, not recruiting10 trials
- Completed3 trials
- Recruiting2 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Memorial Sloan Kettering Cancer Center3 trials
- Pfizer3 trials
- Hoffmann-La Roche2 trials
- Taiho Oncology, Inc.2 trials
- Astellas Pharma Global Development, Inc.1 trial
- and 6 more
Running trials
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, Inc.
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· Phase 1/2· BioNTech SE· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· Phase 2· Genentech, Inc.· Source
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, INC
Active, not recruiting
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
NCT05210790· Phase 3· Protagonist Therapeutics, Inc.· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Olaparib In Metastatic Breast Cancer
NCT03344965· Phase 2· Beth Israel Deaconess Medical Center· Source
Active, not recruiting
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927· Memorial Sloan Kettering Cancer Center· Source
Active, not recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· Phase 3· Pfizer· Source
Active, not recruiting
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
NCT01864109· Phase 2· Memorial Sloan Kettering Cancer Center· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error